EUVIMEDEUVIMED entdecken
Crossref

Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy

Lawrence Zeldin iD, Joanna B S Eichler, Sergio L Teruya iD, Ariel Y Weinsaft iD, Alfonsina Mirabal, Margaret O Cuomo, Kimberly Mateo, Stephen Helmke, Mathew S Maurer iD

European Journal of Heart Failure · 01.12.2025 · 27 (12) · 2961-2970

DOI: 10.1002/ejhf.3540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 05.12.2024. Verfasst von Lawrence Zeldin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial, Cardiomyopathies, Benzoxazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIA NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin cardiomyopathy (ATTR-CM) is characterized by episodes of worsening heart failure (WHF) which can include heart failure (HF) hospitalizations or urgent unplanned visits for administration of intravenous diuretics. WHF characterized by outpatient intensification of oral loop diuretics is common yet its prognostic implications for ATTR-CM patients relative to other WHF events remains unclear. We assessed how WHF characterized by outpatient diuretic intensification (ODI) relates to mortality in this population. Methods and results This was a retrospective study of ATTR-CM patients presenting to the Columbia University Irving Medical Center. Oral loop diuretic dose was recorded longitudinally. WHF characterized by ODI was defined as a persistent increase in oral loop diuretic dose lasting >1 month. We analysed the all-cause mortality rate after either WHF event (hospitalization or ODI) relative to subjects who had no WHF event. Overall, 303 patients highly treated with tafamidis were included: 152 (50.2%) patients had no WHF events, 35 (11.6%) experienced HF hospitalization, and 145 (47.9%) experienced ODI; 29 (9.6%) patients experienced both WHF events. Patients experiencing ODI had higher rates of subsequent mortality (17.7 per 100 person-years; 95% confidence interval [CI] 13.3–23.7) as did those with a HF hospitalization (29.8 per 100 person-years; 95% CI 17.7–50.3) than patients without WHF events (5.0 per 100 person-years; 95% CI 3.0–8.3) on log-rank test. WHF characterized by ODI was independently associated with mortality in a model adjusting for age, genotype, atrial fibrillation, disease duration, time-varying tafamidis use and National Amyloid Centre (NAC) or Columbia stages.

Conclusions

In contemporary patients with ATTR-CM treated with tafamidis, WHF requiring ODI is prognostic of subsequent mortality and is a clinical marker of disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloid Neuropathies, FamilialCardiomyopathiesBenzoxazolesSodium Potassium Chloride Symporter InhibitorsOutpatientsHumansMaleFemaleRetrospective StudiesAgedDisease ProgressionPrognosisMiddle AgedHospitalizationAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

AmyloidosisLoop diureticTransthyretinWorsening heart failure

Substanzen

tafamidisBenzoxazolesSodium Potassium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

ORCID-Profile: Lawrence Zeldin, Sergio L Teruya, Ariel Y Weinsaft, Mathew S Maurer

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging

Zitieren

APA

Zeldin, L., Eichler, J. B. S., Teruya, S. L., Weinsaft, A. Y., Mirabal, A., Cuomo, M. O., Mateo, K., Helmke, S., & Maurer, M. S. (2025). Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure, 27(12), 2961-2970. https://doi.org/10.1002/ejhf.3540

Vancouver

Zeldin L, Eichler JBS, Teruya SL, Weinsaft AY, Mirabal A, Cuomo MO, et al. Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. 2025;27(12):2961-2970. doi:10.1002/ejhf.3540

BibTeX
@article{Zeldin2025,
  author = {Zeldin, Lawrence and Eichler, Joanna B S and Teruya, Sergio L and Weinsaft, Ariel Y and Mirabal, Alfonsina and Cuomo, Margaret O and Mateo, Kimberly and Helmke, Stephen and Maurer, Mathew S},
  title = {Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {2961--2970},
  doi = {10.1002/ejhf.3540}
}
Kostenlos starten →